Global Next-Generation Biologics Market 2016-2020

This market research study analyzes the leading players in the global next-generation biologics market such as Biogen, F. Hoffmann-La Roche, Novo Nordisk, Sanofi, and Takeda Pharmaceuticals. A competitive analysis of this market is also presented by therapies (next-generation regenerative medicine, next-generation antibodies, next-generation insulin products, next-generation recombinant coagulation factors) and by geography (the Americas, APAC, and EMEA). 

Global next-generation biologics market outlook

According to the next generation biologics market analysis, the market is anticipated to witness staggering growth and will post a staggering CAGR of more than 14% during the forecast period. The increasing demand for antibody drug conjugates (ADCs) is one of the major factors driving this market’s growth. ADCs are highly effective cytotoxic drugs linked to a mAbs. These drugs have shown to be potent and efficient in treating diseases, including cancers and hematological malignancies. Therefore, in recent years, antibodies have become the preferred choice to treat respiratory, oncology, and inflammatory diseases.

The use of ADCs, including radioimmunotherapy and antibody-directed enzyme prodrug therapy, has increased significantly. The augmented use of these antibodies in drug development increases revenue generation in the global next-generation biologics market, thereby contributing to market growth.

Next-generation biologics market trends

One of the recent trends gaining traction in the market is the emergence of targeted and combination therapies for the treatment of various diseases such as viral infections and cancer. This is mainly because targeted therapies have fewer side effects than conventional non-targeted therapies. Combination therapies work by targeting multiple mechanisms simultaneously. Targeting multiple pathways in diseases such as cancer, reduce the risk of developing treatment-resistant disorders. As a result, combination therapies, which target distinct mechanisms, are highly efficacious in treating various diseases, which will boost this market’s growth over the next four years.

Next-generation biologics market forecast: Competitive landscape and key vendors

The global next generation biologics market is highly competitive owing to the presence of well-established vendors like F. Hoffmann-La Roche, Sanofi, and Biogen. The entry of these emerging firms is likely to intensify the competition, both regarding innovation and technology during the forecast period. The growth opportunities present in the market also enable the entry of new players.  

Key vendors in the next-generation biologics market

• F. Hofmann-La Roche
• Novo Nordisk
• Sanofi
• Takeda Pharmaceuticals

Next-generation biologics market segmentation by therapies

• Next-generation regenerative medicine
• Next-generation recombinant coagulation factors
• Next-generation antibodies market
• Next-generation insulin products

The next-generation regenerative medicine segment led the market and is expected to dominate the market in the coming years. This segment’s growth is attributed to the increasing demand for tissue-engineered and stem cell products for the treatment of various diseases. Other major factors driving the demand for regenerative products are the increasing government funding in R&D, rising prevalence of chronic diseases, and increasing focus of vendors on cell therapy products.

next-generation biologics market forecast Geographical segmentation and analysis of the next-generation biologics market

• Americas
• APAC
• EMEA

In terms of geography, the next-generation biologics market in the Americas was the fastest growing among other regions and will dominate the market over the next four years. The accelerated approvals for certain formulations will significantly boost this market’s growth in the region. For example, the US FDA granted accelerated approval to daratumumab (DARZALEX) injection for the treatment of multiple myelomas in November 2015. Moreover, the increasing prevalence of cancer, autoimmune diseases, metabolic disorders, and blood disorders in the region will also propel this market’s growth in the Americas until the end of 2020.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global next-generation biologics market?
• What are the key market trends impacting the growth of the global next-generation biologics market?
• What are the challenges to market growth?
• Who are the key vendors in the global next-generation biologics market?
• What are the market opportunities and threats faced by the vendors in the global next-generation biologics market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global next-generation biologics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Biologic Therapeutics Market 2015-2019
• Global Agricultural Biologicals Market 2016-2020
• Global Spine Biologics Market 2016-2020
• Global Wound Biologics Market 2016-2020